


Claims:**1. Compounds of the general formula I****General Formula I**

5

wherein

R¹ represents lower alkyl;**R²** represents aryl; heteroaryl; lower alkyl;

10

R³ represents aryl; heteroaryl;

15

R⁴ represents hydrogen; trifluoromethyl; lower alkyl; lower alkyl-amino; lower alkoxy; lower alkoxy-lower alkoxy; hydroxy-lower alkoxy; lower alkyl-sulfinyl; lower alkylthio; lower alkylthio-lower alkyl; hydroxy-lower alkyl; lower alkoxy-lower alkyl; hydroxy-lower alkoxy-lower alkyl; hydroxy-lower alkyl-amino; lower alkyl-amino-lower alkyl; amino; di-lower alkyl-amino; [N-(hydroxy-lower alkyl)-N-(lower alkyl)]-amino; aryl; aryl-amino; aryl-lower alkyl-amino; aryl-thio; aryl-lower alkyl-thio; aryloxy; aryl-lower alkoxy; aryl-lower alkyl; aryl-sulfinyl; heteroaryl; heteroaryl-oxy; heteroaryl-lower alkyl-oxy; heteroaryl-amino; heteroaryl-lower alkyl-amino; heteroaryl-thio; heteroaryl-lower alkyl-thio; heteroaryl-lower alkyl; heteroaryl-sulfinyl; heterocyclyl; heterocyclyl-lower alkoxy; heterocyclyl-oxy; heterocyclyl-amino; heterocyclyl-lower alkyl-amino; heterocyclyl-thio; heterocyclyl-lower alkyl-thio; heterocyclyl-lower alkyl; heterocyclyl-sulfinyl; cycloalkyl; cycloalkyl-oxy; cycloalkyl-lower alkoxy; cycloalkyl-

20

amino; cycloalkyl-lower alkyl-amino; cycloalkyl-thio; cycloalkyl-lower alkyl-thio;
cycloalkyl-lower alkyl; cycloalkyl-sulfinyl;

X represents oxygen; a bond;

5

Y represents oxygen; -NH-; -NH-SO₂-; -NH-SO₂-NH-; -O-CO-NH-; -NH-CO-O-;
-NH-CO-NH-;

Z represents oxygen; sulfur; -NH-;


10

n represents an integer selected from 2; 3; 4;

and optically pure enantiomers or diastereomers, mixtures of enantiomers or
diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates
and the meso-forms and pharmaceutically acceptable salts thereof.

15

2. Compounds of the formula II:



Formula II

20

wherein


R¹ represents ethyl; propyl; iso-propyl; butyl;

R² represents aryl; heteroaryl;

and R^3 , R^4 and n are as defined in general formula I above and optically pure enantiomers or diastereomers, mixtures of enantiomers or diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates and the meso-forms and pharmaceutically acceptable salts thereof.

5

3. Compounds of the formula III:

**Formula III**

10 wherein

R^1 represents ethyl; propyl; butyl;


R^2 represents aryl; heteroaryl;

15 R^4 represents hydrogen; heteroaryl;

and R^3 is as defined in general formula I above and optically pure enantiomers or diastereomers, mixtures of enantiomers or diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates and the meso-forms and

20 pharmaceutically acceptable salts thereof.

4. Compounds of the formula IV:



wherein


R¹ represents ethyl; propyl; iso-propyl; butyl;

R² represents aryl; heteroaryl

R⁴ represents hydrogen; heteroaryl;

and optically pure enantiomers or diastereomers, mixtures of enantiomers or diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates and the meso-forms and pharmaceutically acceptable salts thereof.

5. Compounds of the formula V




wherein

R^1 , R^2 , R^3 and R^4 as well as Y, Z and n are as defined in general formula I above and optically pure enantiomers or diastereomers, mixtures of enantiomers or diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates and the meso-forms and pharmaceutically acceptable salts thereof.

5

6. Compounds of the formula VI:



Formula VI

10 wherein

R^1 represents ethyl; propyl; butyl;

R^2 represents aryl; heteroaryl;

15 R^4 represents hydrogen or heteroaryl;


A represents hydrogen; methyl; ethyl; chlorine; bromine;

and n represents the integers 2; 3;

20

and optically pure enantiomers or diastereomers, mixtures of enantiomers or diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates and the meso-forms and pharmaceutically acceptable salts thereof.

7. Compounds of the formula VII



Formula VII

5 wherein

R¹ represents ethyl; propyl; butyl;

R² represents heteroaryl;

10 **A** represents methyl; chlorine; bromine;

and optically pure enantiomers or diastereomers, mixtures of enantiomers or diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates and the meso-forms and pharmaceutically acceptable salts thereof.

15

8. The compounds selected from claims 1 to 7

Ethanesulfonic acid {6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-p-tolyl-pyrimidin-4-yl}-amide;

20 n-Propanesulfonic acid {6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-p-tolyl-pyrimidin-4-yl}-amide;

Ethanesulfonic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(4-chloro-phenyl)-pyrimidin-4-yl]-amide;

n-Propanesulfonic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(4-chloro-phenyl)-pyrimidin-4-yl]-amide;

25 Ethanesulfonic acid {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-amide;

n-Propanesulfonic acid {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-amide;

Ethanesulfonic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(2-methoxy-phenoxy)-[2,2']bipyrimidinyl-4-yl]-amide;

5 n-Propanesulfonic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(2-methoxy-phenoxy)-[2,2']bipyrimidinyl-4-yl]-amide;

Ethanesulfonic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-amide;

10 n-Propanesulfonic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-amide;

N-[6-[2-(5-Bromo-pyrimidin-2-yloxy)-ethoxy]-5-p-tolyl-pyrimidin-4-yl]-methanesulfonamide;

Ethanesulfonic acid [5-(2-chloro-5-methoxy-phenoxy)-6-[2-(5-methylsulfanyl-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl]-amide;

15 Butane-1-sulfonic acid [5-(3-methoxy-phenoxy)-6-[2-(5-methylsulfanyl-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl]-amide;

Ethanesulfonic acid [5-(4-bromo-phenyl)-6-[2-(5-methylsulfanyl-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl]-amide;

20 Propane-1-sulfonic acid [5-(2-chloro-5-methoxy-phenoxy)-6-[2-(5-methylsulfanyl-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl]-amide;

and pharmaceutically acceptable salts thereof.

9. The compound selected from claims 1 to 7

25 N-[5-(4-Bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl]-methanesulfonamide;

Ethanesulfonic acid [5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl]-amide;

30 Propane-1-sulfonic acid [5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl]-amide;

Propane-1-sulfonic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-amide;

Ethanesulfonic acid [6-[2-(5-methylsulfanyl-pyrimidin-2-yloxy)-ethoxy]-5-p-tolyl-pyrimidin-4-yl]-amide;

5 Propane-1-sulfonic acid [5-(4-bromo-phenyl)-6-[2-(5-methylsulfanyl-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl]-amide;

Ethanesulfonic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(2-chloro-5-methoxy-phenoxy)-pyrimidin-4-yl]-amide;

10 Propane-1-sulfonic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(2-chloro-5-methoxy-phenoxy)-pyrimidin-4-yl]-amide;

and pharmaceutically acceptable salts thereof.

15 10. Compounds of any one of the claims 1 to 9 for use as medicaments for the treatment of disorders which are associated with a role of endothelin.

11. Compounds of any one of the claims 1 to 9 for use as medicaments for the treatment of circulatory disorders which are associated with a role of endothelin.

20

12. Compounds of any one of the claims 1 to 9 for use as medicaments for the treatment of inflammatory disorders which are associated with a role of endothelin.

13. Compounds of any one of the claims 1 to 9 for use as medicaments for the treatment of proliferative disorders which are associated with a role of endothelin.

25

14. Compounds of any one of the claims 1 to 9 for use as medicaments for the treatment of hypertension, coronary diseases, cardiac insufficiency, renal and myocardial ischemia, renal failure, cerebral ischemia, dementia, migraine, subarachnoidal hemorrhage, Raynaud's syndrome, portal hypertension, pulmonary hypertension, atherosclerosis, prevention of restenosis after balloon or stent

30

angioplasty, inflammation, pulmonary fibrosis, connective tissue diseases, stomach and duodenal ulcer, digital ulcer, cancer, prostatic hypertrophy, erectile dysfunction, hearing loss, amaurosis, chronic bronchitis, asthma, gram negative septicemia, shock, sickle cell anemia, glomerulonephritis, renal colic, glaucoma, complications
5 of vascular or cardiac surgery or after organ transplantation, and complications of cyclosporin, the therapy and prophylaxis of diabetic complications.

15. Compounds of any one of the claims 1 to 9 for use as medicaments for the treatment of disorders which are associated with a role of endothelin, and require
10 mixed ET_A and ET_B blocking for treatment.

16. Compounds of any one of the claims 1 to 9 for use as medicaments for the treatment of disorders which are associated with a role of endothelin, and require selective ET_A blocking for treatment.
15

17. Compounds of any one of the claims 1 to 9 for use as medicaments for the treatment of disorders which are associated with a role of endothelin, and require selective ET_B blocking for treatment.

20 18. The use of one or more compounds of any one of claims 1 to 9 as active ingredients for the production of pharmaceutical compositions for the treatment of disorders associated with a role of endothelin.

19. The use of one or more compounds of any one of claims 1 to 9 as active
25 ingredients for the production of pharmaceutical compositions for the treatment of circulatory disorders which are associated with a role of endothelin.

20. The use of one or more compounds of any one of claims 1 to 9 as active ingredients for the production of pharmaceutical compositions for the treatment of
30 inflammatory disorders which are associated with a role of endothelin.

21. The use of one or more compounds of any one of claims 1 to 9 as active ingredients for the production of pharmaceutical compositions for the treatment of proliferative disorders which are associated with a role of endothelin.

5 22. The use of one or more compounds of any one of claims 1 to 9 as active ingredients for the production of pharmaceutical compositions for the treatment of hypertension, coronary diseases, cardiac insufficiency, renal and myocardial ischemia, renal failure, cerebral ischemia, dementia, migraine, subarachnoidal hemorrhage, Raynaud's syndrome, portal hypertension, pulmonary hypertension,
10 atherosclerosis, prevention of restenosis after balloon or stent angioplasty, inflammation, pulmonary fibrosis, connective tissue diseases, stomach and duodenal ulcer, digital ulcer, cancer, melanoma, prostatic cancer, prostatic hypertrophy, erectile dysfunction, hearing loss, amaurosis, chronic bronchitis, asthma, gram negative septicemia, shock, sickle cell anemia, glomerulonephritis,
15 renal colic, glaucoma, therapy and prophylaxis of diabetic complications, complications of vascular or cardiac surgery or after organ transplantation, and complications of cyclosporin.

23. The use of one or more compounds of any one of claims 1 to 9 as active
20 ingredients in combination with one or more other substances therapeutically useful for the treatment of hypertension, coronary diseases, cardiac insufficiency, renal and myocardial ischemia, renal failure, cerebral ischemia, dementia, migraine, subarachnoidal hemorrhage, Raynaud's syndrome, portal hypertension, pulmonary hypertension, atherosclerosis, prevention of restenosis after balloon or stent
25 angioplasty, inflammation, pulmonary fibrosis, connective tissue diseases, stomach and duodenal ulcer, digital ulcer, cancer, melanoma, prostatic cancer, prostatic hypertrophy, erectile dysfunction, hearing loss, amaurosis, chronic bronchitis, asthma, gram negative septicemia, shock, sickle cell anemia, glomerulonephritis, renal colic, glaucoma, therapy and prophylaxis of diabetic complications,
30 complications of vascular or cardiac surgery or after organ transplantation, and complications of cyclosporin.

24. A process for the manufacture of pharmaceutical compositions for the treatment of disorders associated with a role of endothelin containing one or more compounds as claimed in any one of claims 1 to 9 as active ingredients which process
5 comprises mixing one or more active ingredients with pharmaceutically acceptable excipients in a manner known per se.